IP Due Diligence Partners
Meet the IP Due Diligence team
When Shire decided to create the leading biotechnology company in the world for rare disease products, it looked to its trusted advisors at Carpmaels & Ransford to act as its European IP counsel to pressure-test Baxalta’s expansive patent portfolio in Europe.
Shire had previously sought our due diligence advice on a number of occasions including its purchase of NPS Pharmaceuticals and its acquisition of Foresight Biotherapeutics in 2015. It therefore knew that Carpmaels & Ransford would be able to field an expert team that would act quickly and thoroughly to identify any potential IP hurdles or liabilities.